MTOR - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
ESR1	estrogen receptor 1	Nuclear signaling by ERBB4 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Ovarian tumor domain proteases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors RUNX1 regulates estrogen receptor mediated transcription ESR-mediated signaling RUNX1 regulates transcription of genes involved in WNT signaling Regulation of RUNX2 expression and activity Regulation of RUNX2 expression and activity Extra-nuclear estrogen signaling Estrogen-dependent gene expression	Diethylstilbestrol Chlorotrianisene Conjugated estrogens Desogestrel Levonorgestrel Progesterone Lindane Raloxifene Toremifene Medroxyprogesterone acetate Testosterone Mitotane Estrone Tamoxifen Hexachlorophene Estradiol Ethynodiol diacetate Dobutamine Clomifene Dienestrol Fulvestrant Norgestimate Ethinylestradiol Melatonin Trilostane Naloxone Fluoxymesterone Estramustine Mestranol Danazol Oxybenzone Allylestrenol Zinc Genistein Prasterone Benzophenone Equilin Compound 19 Resveratrol Compound 18 Phthalic Acid Pyrazole Stanolone Naringenin Compound 4-D 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Quercetin Afimoxifene 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol Estriol Estrone sulfate Quinestrol Phenolphthalein Permethrin Ospemifene AP1081 Custirsen NP-50301 CHF 4227 TAS-108 Lasofoxifene Arzoxifene Elacestrant Bazedoxifene Methyltestosterone beta-Naphthoflavone 17-METHYL-17-ALPHA-DIHYDROEQUILENIN 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL Hexestrol dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate Erteberel N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol Tibolone Eugenol Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, B Polyestradiol phosphate Norethynodrel Octocrylene Homosalate Enzacamene Zeranol Ractopamine Gestrinone Propyl Gallate 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol Testosterone cypionate Testosterone enanthate Testosterone undecanoate Stanolone acetate Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate Zinc acetate Zinc chloride Zinc sulfate, unspecified form Estriol tripropionate Fluoroestradiol F-18
FBXO8	F-box protein 8
FKBP1A	FKBP prolyl isomerase 1A	mTORC1-mediated signalling Calcineurin activates NFAT Calcineurin activates NFAT TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGFBR1 LBD Mutants in Cancer Potential therapeutics for SARS	Pimecrolimus Tacrolimus Sirolimus (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid Gpi-1046 Methyl Methylsulfinylmethyl Sulfide FKB-001 Heptyl glucoside L-709,587 (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine 4-hydroxybutan-2-one GPI-1485 Myristic acid (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE Dorsomorphin
FKBP8	FKBP prolyl isomerase 8	Ub-specific processing proteases
GPHN	gephyrin	Molybdenum cofactor biosynthesis	Formic acid Imidazole Propanoic acid	Hyperekplexia
GSK3B	glycogen synthase kinase 3 beta	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade AKT phosphorylates targets in the cytosol Regulation of HSF1-mediated heat shock response CRMPs in Sema3A signaling Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane B-WICH complex positively regulates rRNA expression Signaling by GSK3beta mutants S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Constitutive Signaling by AKT1 E17K in Cancer Ubiquitin-dependent degradation of Cyclin D Regulation of RUNX2 expression and activity Replication of the SARS-CoV-1 genome Maturation of nucleoprotein Maturation of nucleoprotein Maturation of nucleoprotein Replication of the SARS-CoV-2 genome	Lithium cation 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione SB-409513 AR-AO-14418 Staurosporine Indirubin-3'-monoxime 6-bromoindirubin-3'-oxime Alsterpaullone Phosphoaminophosphonic Acid-Adenylate Ester 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE Fostamatinib Tideglusib Lithium citrate Lithium succinate Lithium carbonate
HRAS	HRas proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants	Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Bladder cancer Penile cancer Squamous cell carcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
IRS1	insulin receptor substrate 1	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Growth hormone receptor signaling	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
MAF1	MAF1 homolog, negative regulator of RNA polymerase III	Regulation of PTEN gene transcription Regulation of PTEN gene transcription
MLST8	MTOR associated protein, LST8 homolog	PIP3 activates AKT signaling Macroautophagy MTOR signalling mTORC1-mediated signalling HSF1-dependent transactivation Energy dependent regulation of mTOR by LKB1-AMPK CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of PTEN gene transcription Amino acids regulate mTORC1
NRAS	NRAS proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
PA2G4	proliferation-associated 2G4	Neutrophil degranulation
PDPK1	3-phosphoinositide dependent protein kinase 1	GPVI-mediated activation cascade GPVI-mediated activation cascade PIP3 activates AKT signaling Activation of AKT2 Downstream TCR signaling Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated NF-kB activation Integrin signaling CD28 dependent PI3K/Akt signaling G beta:gamma signalling through PI3Kgamma RSK activation VEGFR2 mediated vascular permeability VEGFR2 mediated cell proliferation CLEC7A (Dectin-1) signaling RHO GTPases activate PKNs Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Estrogen-stimulated signaling through PRKCZ Estrogen-stimulated signaling through PRKCZ	Celecoxib Inositol 1,3,4,5-Tetrakisphosphate 7-Hydroxystaurosporine Bisindolylmaleimide VIII Staurosporine Bisindolylmaleimide I Dexfosfoserine 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE Fostamatinib
PLD2	phospholipase D2	Synthesis of PG Synthesis of PA Role of phospholipids in phagocytosis	Choline Choline salicylate
PPP2R2A	protein phosphatase 2 regulatory subunit Balpha	Initiation of Nuclear Envelope (NE) Reformation Cyclin D associated events in G1 Cyclin A/B1/B2 associated events during G2/M transition Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid
PREX1	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1	NRAGE signals death through JNK Rho GTPase cycle G alpha (12/13) signalling events
PRKAA1	protein kinase AMP-activated catalytic subunit alpha 1	Macroautophagy Energy dependent regulation of mTOR by LKB1-AMPK TP53 Regulates Metabolic Genes Regulation of TP53 Activity through Phosphorylation Activation of AMPK downstream of NMDARs	Adenosine phosphate Adenosine phosphate ATP Phenformin Acetylsalicylic acid Fostamatinib Fostamatinib
PRKCA	protein kinase C alpha	Calmodulin induced events Disinhibition of SNARE formation SHC1 events in ERBB2 signaling Signaling by SCF-KIT Regulation of KIT signaling EGFR Transactivation by Gastrin Inactivation, recovery and regulation of the phototransduction cascade Syndecan interactions Acetylcholine regulates insulin secretion Ca2+ pathway Trafficking of GluR2-containing AMPA receptors G alpha (z) signalling events Depolymerisation of the Nuclear Lamina HuR (ELAVL1) binds and stabilizes mRNA WNT5A-dependent internalization of FZD4 VEGFR2 mediated cell proliferation RHO GTPases Activate NADPH Oxidases Response to elevated platelet cytosolic Ca2+ RET signaling ROBO receptors bind AKAP5 ROBO receptors bind AKAP5	Phosphatidyl serine Vitamin E Tamoxifen Ingenol mebutate Aprinocarsen Midostaurin Perifosine Ellagic acid Bryostatin 1 alpha-Tocopherol succinate D-alpha-Tocopherol acetate
PRR5L	proline rich 5 like
RHEB	Ras homolog, mTORC1 binding	Macroautophagy MTOR signalling mTORC1-mediated signalling Energy dependent regulation of mTOR by LKB1-AMPK TP53 Regulates Metabolic Genes Regulation of PTEN gene transcription Amino acids regulate mTORC1	Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate

Search Results for: MTOR